Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
==== Russia ==== According to the Foreign Policy Research Institute, Russia has 112 think tanks, while Russian think tanks claimed four of the top ten spots in 2011's "Top Thirty Think Tanks in Central and Eastern Europe". Notable Russian think tanks include:
== Milk types == Kefir grains will ferment the milk from most mammals and will continue to grow in such milk. Typical animal milks used include cow, goat, and sheep, each with varying organoleptic (flavor, aroma, and texture) and nutritional qualities. Raw milk has been traditionally used. Milk sugar is not essential for the synthesis of the polysaccharide that makes up the grains (kefiran), and rice hydrolysate is a suitable alternative medium. Additionally, kefir grains will reproduce when fermenting soy milk, although they will change in appearance and size due to the differing proteins available to them. A different type of SCOBY that thrives in sugary water also exists, called water kefir (or tibicos), and can vary markedly from milk kefir in both appearance and microbial composition.
In 1944, it was officially decided to abolish the conventional name "Improved Japanese Breed" and call the breeds Japanese Black, Japanese Brown, and Japanese Polled, as the characteristics of each breed had been clarified as a result of improvements. This officially recognized the three crossbreeds as fixed breeds. Then, in 1957, the Japanese Shorthorn was added. They are collectively known as Wagyu. The Uruguay Round of the General Agreement on Tariffs and Trade (GATT) from 1986 to 1994, which set rules for liberalization of international trade, decided to liberalize imports of foreign beef to Japan. Beef imports have been liberalized since 1991. In 1993, beef imports jumped 34% over the previous year, and as a result, Japan's beef self-sufficiency rate dropped below 50%. The liberalization of beef imports has brought about changes in Japan's domestic Wagyu beef production system. In order to compete with cheaper foreign beef, Japanese livestock farmers have become more focused on raising the Japanese Black breed, which has a unique marbling characteristic. As a result, the number of the other three Wagyu breeds has decreased. Following the outbreak of Bovine Spongiform Encephalopathy (BSE) in Japan, the Law for Special Measures Concerning the Management and Relay of Information for Individual Identification of Cattle (Beef Traceability Law) was enacted in 2003. This law stipulates the attachment of ear tags to cattle, the notification, recording, and storage of historical information from birth to beef, and the publication of recorded information on the Internet.
The thymus continues to grow after birth, reaching the relative maximum size by puberty. It is most active in fetal and neonatal life. It increases to a mass of 20 to 50 grams by puberty. It then begins to decrease in size and activity in a process called thymic involution. After the first year of life the amount of T cells produced begins to fall. Fat and connective tissue fill a part of the thymic volume. During involution, the thymus decreases in size and activity. Fat cells are present at birth, but increase in size and number markedly after puberty, invading the gland from the walls between the lobules first, then into the cortex and medulla. This process continues into old age, where whether with a microscope or with the human eye, the thymus may be difficult to detect, although typically weighs 5–15 grams. Additionally, there is an increasing body of evidence showing that age-related thymic involution is found in most, if not all, vertebrate species with a thymus, suggesting that this is an evolutionary process that has been conserved.[40] The atrophy is due to the increased circulating level of sex hormones, and chemical or physical castration of an adult results in the thymus increasing in size and activity. Severe illness or human immunodeficiency virus infection may also result in involution.
Sources: en.wikipedia.org
Kanury Rao also known as Kanury Venkata Subba Rao (born 1958) is an Indian immunologist. He was the head of the Drug Discovery Research Centre (DDRC) at the Translational Health Science and Technology Institute (THSTI) Faridabad. He is known for his studies in the fields of peptide synthesis and cell signaling and the design of synthetic peptide vaccines. He is an elected fellow of the Indian Academy of Sciences, National Academy of Sciences, India and the Indian National Science Academy. and a recipient of several awards including the Millennium Plaque of Honour of the Indian Science Congress and the National Bioscience Award for Career Development. The Council of Scientific and Industrial Research awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, in 1997, for his contributions to biological sciences.
==== Standard ==== Tryptophan is a precursor of the neurotransmitter serotonin. Tyrosine (and its precursor phenylalanine) are precursors of the catecholamine neurotransmitters dopamine, epinephrine and norepinephrine and various trace amines. Phenylalanine is a precursor of phenethylamine and tyrosine in humans. In plants, it is a precursor of various phenylpropanoids, which are important in plant metabolism. Glycine is a precursor of porphyrins such as heme. Arginine is a precursor of nitric oxide. Ornithine and S-adenosylmethionine are precursors of polyamines. Aspartate, glycine, and glutamine are precursors of nucleotides.
== Interactions == Vortioxetine is metabolized primarily by the cytochrome P450 enzyme CYP2D6. Inhibitors and inducers of CYP2D6 may modify the pharmacokinetics of vortioxetine and necessitate dosage adjustments. Bupropion, a strong CYP2D6 inhibitor, has been found to increase peak levels of vortioxetine by 2.1-fold and total vortioxetine levels by 2.3-fold (bupropion dosed at 300 mg/day and vortioxetine dosed at 10 mg/day). The incidence of side effects with vortioxetine, like nausea, headache, vomiting, and insomnia, was correspondingly increased with the combination. Other strong CYP2D6 inhibitors, like fluoxetine, paroxetine, and quinidine, may have similar influences on the pharmacokinetics of vortioxetine, and it is recommended that the dosage of vortioxetine be reduced by half when it is administered in combination with such medications. Lesser interactions have additionally been identified for vortioxetine with the cytochrome P450 inhibitors ketoconazole and fluconazole. Rifampicin, a strong and broad cytochrome P450 inducer (though notably not of CYP2D6), has been found to decrease peak levels of vortioxetine by 51% and total levels of vortioxetine by 72% (rifampicin dosed at 600 mg/day and vortioxetine at 20 mg/day). Similar influences on vortioxetine pharmacokinetics may also occur with other strong cytochrome P450 inducers including carbamazepine and phenytoin. As such, increasing vortioxetine dosage should be considered when it is given in combination with strong cytochrome P450 inducers.
==== Democratic reaction ==== The narrow passage of OBBBA led to internal backlash and division in the Democratic Party. Three elderly Democratic representatives (Raúl Grijalva of Arizona, age 77; Sylvester Turner of Texas, age 70; and Gerry Connolly of Virginia, age 75) died in the first five months of 2025. If any of the three had been alive when the vote was taken, the result of the vote could have been different. The vote "quickly reignited an intraparty debate about gerontocracy and aging politicians clinging to power".
There are concerns that some users may find it hard to stop using TikTok. Internal TikTok research has documented the addiction potential of the app. In April 2018, an addiction-reduction feature was added to Douyin. This encouraged users to take a break every 90 minutes. Later in 2018, the feature was rolled out to the TikTok app. TikTok uses popular influencers to encourage viewers to stop using the app and take a break. Many were also concerned with the app affecting users' attention spans due to the short-form nature of the content. This is a concern as many of TikTok's audience are younger children, whose brains are still developing. TikTok executives and representatives have noted and made aware to advertisers on the platform that users have poor attention spans. The company's survey reported that nearly 50% of social media users find it stressful to watch a video longer than a minute and a third of users watch videos at double speed. Their short attention spans posed a challenge for TikTok to pivot towards longer content formats. TikTok has also received criticism for enabling children to purchase coins which they can send to other users. Daily hours of entertainment screen media (Social Medias) may displace healthy behaviors such as socializing face to face, chores, hobbies, homework, family meals time, exercise, and sufficient sleep. Insomnia is considered a strong mediator between screen media time and mental health symptoms which implies that engaging in screen time pushes out adequate sleep and leads to decreased mental health.
Sources: en.wikipedia.org
=== Category:EC 3.3 (act on ether bonds) === Category:EC 3.3 Adenosylmethionine hydrolase S-adenosyl-L-homocysteine hydrolase Alkenylglycerophosphocholine hydrolase Alkenylglycerophosphoethanolamine hydrolase Cholesterol-5,6-oxide hydrolase Hepoxilin-epoxide hydrolase Isochorismatase Leukotriene-A4 hydrolase Limonene-1,2-epoxide hydrolase Microsomal epoxide hydrolase Trans-epoxysuccinate hydrolase
=== Leaderless initiation === A number of bacterial mRNAs have no 5'UTR whatsoever, or a very short one. The complete 70S ribosome, with the help of IF2 (recruiting fMet-tRNA), can simply start translating such a "leaderless" mRNA. A number of factors modify the efficiency of leaderless initiation. A 5' phosphate group attached to the start codon seems near-essential. AUG is strongly preferred in E. coli, but not necessarily in other species. IF3 inhibits leaderless initiation. A longer 5'UTR or one with significant secondary structure also inhibits leaderless initiation.
=== Fibromyalgia === Patients with fibromyalgia often report unrefreshing sleep. A study conducted in 1975 by Moldovsky et al. showed that the delta wave activity of these patients in stages 3 and 4 sleep were often interrupted by alpha waves. They later showed that depriving the body of delta wave sleep activity also induced musculoskeletal pain and fatigue.
== Treatment == To contain the virus, cats with suspected or diagnosed FPLV should be kept in isolation. It requires immediate, aggressive treatment if the cat is to survive, as it can be fatal in less than 24 hours. Several articles and publications provide guidance for rescuers and veterinarians for optimizing outcomes. Treatment involves:
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.